TABLE 4.
Logistic regression model for latent tuberculosis infection (LTBI) testing uptake, comparing individuals with an interferon-γ release assay (IGRA) test result (IGRA done) to individuals who were offered LTBI testing but had no recorded IGRA test result (IGRA not done)
| Characteristic | IGRA not done n (%#) | IGRA done n (%#) | Chi-squared p-value | Univariable analysis | Multivariable analysis | |||||
| OR | 95% CI | p-value | aOR | 95% CI | p-value | Likelihood ratio | ||||
| Age group | 0.002 | |||||||||
| <16 years | 26 (59.1) | 18 (40.9) | 1.1 | 0.6–1.9 | 0.9 | 1.1 | 0.6–2.0 | 0.7 | ||
| 16–35 years | 2396 (60.4) | 1572 (39.6) | Comparison group | Comparison group | ||||||
| 36–50 years | 788 (58.6) | 556 (41.4) | 1.1 | 0.9–1.2 | 0.2 | 1.1 | 1–1.3 | 0.03 | ||
| >50 years | 112 (47.7) | 123 (52.3) | 1.7 | 1.3–2.2 | <0.001 | 1.8 | 1.4–2.4 | <0.001 | ||
| Sex | 0.8 | |||||||||
| Female | 1527 (59.6) | 1036 (40.4) | Comparison group | Comparison group | ||||||
| Male | 1795 (59.3) | 1233 (40.7) | 1.01 | 0.9–1.1 | 0.8 | 1 | 0.9–1.1 | 0.8 | 0.8523 | |
| Region of birth | <0.001 | |||||||||
| East and South-East Asia | 99 (72.3) | 38 (27.7) | 0.5 | 0.3–0.7 | 0.001 | 0.6 | 0.4–0.9 | 0.02 | ||
| Eastern Europe | 3 (37.5) | 5 (62.5) | 2.2 | 0.5–9.3 | 0.3 | 2.5 | 0.6–10.5 | 0.2 | ||
| Northern Africa and Middle East | 7 (63.6) | 4 (36.4) | 0.8 | 0.2–2.6 | 0.7 | 0.7 | 0.2–2.5 | 0.6 | ||
| Southern Asia | 2512 (57.3) | 1875 (42.7) | Comparison group | Comparison group | ||||||
| Sub-Saharan Africa | 701 (66.9) | 347 (33.1) | 0.6 | 0.6–0.8 | <0.001 | 0.7 | 0.6–0.8 | <0.001 | <0.001 | |
| BCG | 0.2 | |||||||||
| No | 3299 (59.5) | 2246 (40.5) | Comparison group | |||||||
| Yes | 23 (50.0) | 23 (50.0) | 1.5 | 0.8–2.6 | 0.2 | |||||
| Immunosuppression | 0.4 | |||||||||
| No | 3321 (59.4) | 2269 (40.6) | Comparison group | |||||||
| Yes | 1 (100.0) | 0 (0.0) | n/a | n/a | n/a | |||||
| Diabetes mellitus | 0.04 | |||||||||
| No | 3168 (59.7) | 2136 (40.3) | Comparison group | Comparison group | ||||||
| Yes | 154 (53.7) | 133 (46.3) | 1.3 | 1–1.6 | 0.04 | 1.04 | 0.8–1.3 | 0.8 | 0.7134 | |
| Pre-existing lung disease | 0.98 | |||||||||
| No | 3214 (59.4) | 2195 (40.6) | Comparison group | |||||||
| Yes | 108 (59.3) | 74 (40.7) | 1 | 0.7–1.3 | 0.98 | |||||
| Chronic liver disease | 0.03 | |||||||||
| No | 3279 (59.6) | 2223 (40.4) | Comparison group | Comparison group | ||||||
| Yes | 43 (48.3) | 46 (51.7) | 1.6 | 1.04–2.4 | 0.03 | 1.6 | 1.1–2.5 | 0.02 | 0.0341 | |
| Chronic kidney disease | 0.6 | |||||||||
| No | 3306 (59.4) | 2260 (40.6) | Comparison group | |||||||
| Yes | 16 (64.0) | 9 (36.0) | 0.8 | 0.4–1.9 | 0.6 | |||||
| Current smoker | 0.006 | |||||||||
| No | 2787 (58.7) | 1964 (41.3) | Comparison group | Comparison group | ||||||
| Yes | 535 (63.7) | 305 (36.3) | 0.8 | 0.7–0.9 | 0.006 | 0.8 | 0.7–0.9 | 0.01 | 0.0031 | |
| General practice group | <0.001 | |||||||||
| Cluster 1 | 930 (67.9) | 440 (32.1) | Comparison group | Comparison group | ||||||
| Cluster2 | 258 (63.2) | 150 (36.8) | 1.2 | 1.0–1.5 | 0.08 | 1.2 | 1.0–1.5 | 0.09 | ||
| Cluster 3 | 412 (50.7) | 401 (49.3) | 2.1 | 1.7–2.5 | <0.001 | 2.0 | 1.7–2.4 | <0.001 | ||
| Cluster 4 | 463 (49.4) | 475 (50.6) | 2.2 | 1.8–2.6 | <0.001 | 2.1 | 1.8–2.5 | <0.001 | ||
| Cluster 5 | 512 (62.6) | 306 (37.4) | 1.3 | 1.1–1.5 | 0.01 | 1.3 | 1.1–1.6 | 0.006 | ||
| Cluster 6 | 285 (51.6) | 267 (48.4) | 2.0 | 1.6–2.4 | <0.001 | 2.0 | 1.6–2.5 | <0.001 | ||
| Cluster 7 | 287 (70.7) | 119 (29.3) | 0.9 | 0.7–1.1 | 0.3 | 0.9 | 0.7–1.2 | 0.7 | ||
| Cluster 8 | 131 (61.2) | 83 (38.8) | 1.3 | 1.0–1.8 | 0.05 | 1.5 | 1.1–2.0 | 0.01 | <0.001 | |
#: proportions calculated out of each characteristic as row proportions.